Lilly

United Stateslilly.com

Its roles Owner Operator

projects tracked
11
active
8
countries
4
plants
9

Eli Lilly and Company (Lilly; NYSE: LLY) is a U.S.-based global pharmaceutical manufacturer that discovers, develops, and produces medicines for human health. Founded in 1876 and headquartered in Indianapolis, Indiana, the company’s portfolio spans small‑molecule and biologic therapies, with core focus areas including diabetes and metabolic diseases, immunology, oncology, and neuroscience.

Read more

Across the chemicals and life‑sciences value chain, Lilly operates extensive R&D and manufacturing networks for active pharmaceutical ingredients (APIs), biologics, and sterile injectable formulations, supported by global quality, regulatory, and supply‑chain systems. The company also develops drug‑delivery devices and collaborates with academic and industry partners to advance new therapeutic modalities.

Also known as Eli Lilly, Lilly USA, LLY, Eli Lilly USA, LLC, and Eli Lilly and Company.

Projects Lilly is involved in

chemXplore tracks 11 projects involving Lilly, of which 8 are active.

  1. 4 projects Announced / Concept
  2. none FEED / Pre-FID
  3. none FID / Sanctioned
  4. 4 projects Under Construction
  5. none Commissioning & Start-up

Besides these 8, the record holds 3 completed projects.

Active projects

Closest to start-up first.

2 more active projects and the 3 that are completed, on hold or cancelled are in the record. See all 11 in chemXplore

Expected start-up, by year
0 1 2 3 2026 2027 2028 2029 2030 2031

1 active project carries no start-up date yet. The dates themselves, per project, are for subscribers.

What moved recently

  • 12 November 2026 Lilly Lehigh Valley injectable medicine and device plant · Under Construction · United States
  • 22 October 2026 Lilly Goochland bioconjugate API and drug product plant · Under Construction · United States
  • 21 September 2026 Lilly Houston API plant · Under Construction · United States
  • 6 May 2026 Lilly Lebanon API and Advanced Therapies expansion · Announced / Concept · United States
  • 9 December 2025 Lilly Huntsville API plant · Announced / Concept · United States

Lilly in chemical industry news

12 November 2026
Lilly starts construction of $3.5bn obesity-medicine plant in Pennsylvania

The Fogelsville facility will make injectable medicines, including investigational retatrutide, and is expected to be operational by 2031.

11 November 2026
Lilly reports one-year data on Taltz and Zepbound combination

ACR50 response reached 43.7% versus 15.7% with Taltz alone; exploratory results also showed metabolic and patient-reported improvements.

9 November 2026
Lilly's Foundayo (orforglipron) cuts OSA severity and hypoxic burden in Phase 3 ATTAIN-OSA

Phase 3 ATTAIN-OSA showed up to 44% AHI reduction, up to 55.9% lower hypoxic burden, ~11–11.5% weight loss, and improvements in blood pressure and inflammation; FDA submission planned by end of 2026.

6 November 2026
Lilly and Hims & Hers broaden access to Lilly’s Zepbound and Foundayo

Eligible patients can obtain Zepbound (tirzepatide) and Foundayo (orforglipron) via Hims & Hers telehealth with self-pay prices from $149/month for Foundayo and $299/month for Zepbound.

5 November 2026
Lilly showcases retatrutide, Taltz (ixekizumab) and Zepbound (tirzepatide) data at ACR Convergence 2026

Phase 3 TRIUMPH trials showed retatrutide cut knee pain by up to 75.8% with some patients pain‑free; TOGETHER‑PsA found ixekizumab plus tirzepatide raised ACR50 to 43.7% at 52 weeks.

29 October 2026
Lilly raises 2026 guidance after Q3 revenue surge driven by Mounjaro and Zepbound

Q3 revenue rose 39% to $24.4B; 2026 revenue outlook raised to $91–$92B. Q3 included ~$900M of benefits and $4.2B IPR&D charges; multiple FDA approvals and positive late‑stage readouts reported.

28 October 2026
Lilly’s retatrutide outperforms Ozempic 2 mg in A1C and weight loss in Phase 3 head‑to‑head

At 80 weeks retatrutide lowered A1C by 2.2% and reduced weight ~20% (44–47 lbs) versus Ozempic 2 mg’s 1.8% A1C reduction and 9.4% (~21 lbs) weight loss.

25 October 2026
Lilly's olomorasib shows durable first-line activity in KRAS G12C NSCLC

Durable PFS and DOR not reached with immunotherapy combo; chemoimmunotherapy combo showed 62% ORR and 14.5‑month median DOR in first-line KRAS G12C NSCLC.

Where its projects are

active all projects

chemXplore Cluster Watch · updated daily
The 16 chemical clusters of Northwest Europe, read as one system
Hydrogen CO2 Oil, gas and chemicals Heat and power
Open the map

Partners on its projects